Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

Add To Watchlist

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Vyzulta

View:

Post by johnnywick on Aug 02, 2017 4:40pm

Vyzulta

Vyzulta market opportunity

According to Valeant’s estimates, approximately 3 million people in the United States have glaucoma. The company has valued the total US glaucoma market opportunity at close to $3.0 billion. Prostaglandin-analog class drugs, such as Vyzulta, account for $1.6 billion of the glaucoma market. While 17 million prostaglandin prescriptions are written annually in the country, around 70% are for the latanoprost molecule.

In a phase 2b dose-ranging trial, Vyzulta demonstrated higher efficacy in reducing intraocular pressure than Pfizer’s (PFE) Xalatan. The drug also established a solid clinical and safety profile in subsequent phase 3 trials. If approved, Vyzulta will make Valeant tough competition for glaucoma players Novartis (NVS) and Allergan (AGN).